Ana Vanessa Wren

Dr. Ana Vanessa Wren

Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in Children
Verified
Journal Article
Open access
PDF file
AWAna Vanessa Wren
Ana Vanessa Wren
ARAlexandra C. Ross
Alexandra C. Ross
GDGenevieve D’Souza
Genevieve D’Souza
CAChristina Almgren
Christina Almgren
AFAmanda Feinstein
Amanda Feinstein
BGBrenda Golianu
Brenda Golianu
Opioid therapy is the cornerstone of treatment for acute procedural and postoperative pain and is regularly prescribed for severe and debilitating chronic pain conditions. Although beneficial for many patients, opioid therapy may have side effects, limited efficacy, and potential negative outcomes. Multidisciplinary pain management treatments incorporating pharmacological and integrative non-pharmacological therapies have been shown to be effective in acute and chronic pain management for pediatric populations. A multidisciplinary approach can also benefit psychological functioning and quality of life, and may have the potential to reduce reliance on opioids. The aims of this paper are to: (1) provide a brief overview of a multidisciplinary pain management approach for pediatric patients with acute and chronic pain, (2) highlight the mechanisms of action and evidence base of commonly utilized integrative non-pharmacological therapies in pediatric multidisciplinary pain management, and (3) explore the opioid sparing effects of multidisciplinary treatment for pediatric pain.

31 January 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
AWAna Vanessa Wren
Ana Vanessa Wren
RSRebecca A. Shelby
Rebecca A. Shelby
MSMary Scott Soo
Mary Scott Soo
ZHZenzi Huysmans
Zenzi Huysmans
JJJennifer A. Jarosz
Jennifer A. Jarosz
FKFrancis J. Keefe
Francis J. Keefe

7 July 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
AWAna Vanessa Wren
Ana Vanessa Wren
RBRachel Bensen
Rachel Bensen
LSLindsay Sceats
Lindsay Sceats
MDMelody Dehghan
Melody Dehghan
HYHelen Yu
Helen Yu
KPK T Park
K T Park
Opioids are commonly prescribed for relief in inflammatory bowel disease (IBD). Emerging evidence suggests that adolescents and young adults are a vulnerable population at particular risk of becoming chronic opioid users and experiencing adverse effects. This study evaluates trends in the prevalence and persistence of chronic opioid therapy in adolescents and young adults with IBD in the United States. A longitudinal retrospective cohort analysis was conducted with the Truven MarketScan Database from 2007 to 2015. Study subjects were 15–29 years old with ≥2 IBD diagnoses (Crohn’s: 555/K50; ulcerative colitis: 556/K51). Opioid therapy was identified with prescription claims within the Truven therapeutic class 60: opioid agonists. Persistence of opioid use was evaluated by survival analysis for patients who remained in the database for at least 3 years following index chronic opioid therapy use. In a cohort containing 93,668 patients, 18.2% received chronic opioid therapy. The annual prevalence of chronic opioid therapy increased from 9.3% in 2007 to 10.8% in 2015 (P < 0.01), peaking at 12.2% in 2011. Opioid prescriptions per patient per year were stable (approximately 5). Post hoc Poisson regression analyses demonstrated that the number of opioid pills dispensed per year increased with age and was higher among males. Among the 2503 patients receiving chronic opioid therapy and followed longitudinally, 30.5% were maintained on chronic opioid therapy for 2 years, and 5.3% for all 4 years. Sustained chronic opioid use in adolescents and young adults with IBD is increasingly common, underscoring the need for screening and intervention for this vulnerable population.

5 May 2021 in Children
Verified
Journal Article
Open access
PDF file
AWAna Vanessa Wren
Ana Vanessa Wren
NNNicole Neiman
Nicole Neiman
TCThomas J. Caruso
Thomas J. Caruso
SRSamuel Rodriguez
Samuel Rodriguez
Katherine TaylorKatherine Taylor
Katherine Taylor
LNLinda Nguyen
Linda Nguyen
The aim of this pilot study was to assess: (1) the feasibility and acceptability of a Mindfulness-Based Virtual Reality (MBVR) intervention among children and young adults with Inflammatory Bowel Disease (IBD), and (2) the preliminary efficacy of MBVR on key psychological (anxiety) and physical (pain) outcomes. Participants were 62 children to young adults with IBD (M = 15.6 years; 69.4% Crohn’s disease; 58% male) recruited from an outpatient pediatric IBD clinic. Participants completed a baseline assessment, underwent the 6-min MBVR intervention, completed a post-intervention assessment and study satisfaction survey, and provided qualitative feedback. Results suggest strong feasibility and acceptability. Participants reported high levels of satisfaction with MBVR including high levels of enjoyment (M = 4.38; range 1–5) and relaxation (M = 4.35; range 1–5). Qualitative data revealed several key themes including participants interest in using MBVR in IBD medical settings (e.g., hospitalizations, IBD procedures, IBD treatments), as well as in their daily lives to support stress and symptom management. Preliminary analyses demonstrated improvements in anxiety (t = 4.79, p = 0.001) and pain (t = 3.72, p < 0.001) following MBVR. These findings provide initial support for the feasibility and acceptability of MBVR among children and young adults with IBD. Results also suggest MBVR may improve key IBD outcomes (e.g., anxiety, pain) and highlight the importance of conducting a randomized controlled trial and more rigorous research to determine intervention efficacy.

3 April 2017 in Children
Verified
Journal Article
Open access
PDF file
AYAnn Ming Yeh
Ann Ming Yeh
AWAna Vanessa Wren
Ana Vanessa Wren
BGBrenda Golianu
Brenda Golianu
Pediatric inflammatory bowel disease is an autoimmune disease that causes chronic inflammation of the gastrointestinal mucosa. There is emerging evidence that the brain–gut connection affects inflammatory bowel disease (IBD) patients more than previously thought. This is evidenced by comorbid mood disorders, irritable bowel symptoms concurrent with quiescent IBD, and the potential of psychosocial stressors to trigger IBD flares. Mind–body interventions such as psychotherapy, relaxation, mindfulness, biofeedback, yoga, and clinical hypnosis offer an adjunct to standard medical treatment for IBD. We will review the current evidence base for these mind– body interventions in the treatment of pediatric IBD, illustrate a case study, and offer suggestions for future research for this promising field.

23 February 2021 in Children
Verified
Journal Article
Open access
PDF file
AWAna Vanessa Wren
Ana Vanessa Wren
Michele MadduxMichele Maddux
Michele Maddux
Inflammatory Bowel Disease (IBD) is a chronic and relapsing inflammatory disorder of the gastrointestinal tract